A new global licensing agreement is set to advance development of an oncology biosimilar candidate.
Initiation of the licensing agreement will help Teva to grow its biosimilar pipeline. mAbxience will be able to further its global expansion strategy.
The deal covers several drug markets worldwide, including in
Based on the agreement, Teva stated that by leading the regulatory processes and commercialisation in planned regions, the company will facilitate broader access of the biosimilar to eligible patients.
Under the terms of the new arrangement, mAbxience will develop and produce the biosimilar product using its expertise in biosimilar development and its current Good Manufacturing Practice (cGMP)-approved facilities located in
Biosimilars market
A report published by
"This agreement will assist healthcare systems in reducing costs, ensuring the provision of these vital cancer treatments to all patients who require them”
"This collaboration reflects Teva's ideal strategic partnership model to optimise development costs, mitigate risk and leverage our extensive commercial capabilities," stated
The new partnership aligns with mAbxience's mission "to deliver high-quality, affordable healthcare solutions across continents," commented
The post Teva enters into oncology biosimilar licensing agreement appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source